InstructorRoyed Training
TypeOnline Course
Student Enrolled1
Price$790 / 55300 INR.
Buy NowBook Now
Loading
Loading
eu regulatory affairs

Introduction

who should attend

Feature

Related Courses

Core Topics

The objective of EU Drug Biologic Medical Device Regulatory Affairs course provides hands on marketing authorization approval and management. This comprehensive course provides participants with a thorough understanding of the regulatory framework governing the development, approval, and marketing of healthcare products in the EU.

EU regulatory affairs course covers recent pharmaceutical regulations, marketing authorization procedure, country specific Common Technical Documents requirement. Moreover, comprehensive ideas are provided on how to prepare drug and medical device dossiers as per EU CTD and EU MDR format. Moreover the course focuses on the various marketing authorization pathways. Above all, course briefs on strategic planning for registration of pharmaceutical, biopharmaceuticals in the European Union.

This online course utilizes interactive learning tools to guide each participant through to understand the EU regulatory structure and ensure that your submissions meet the standards required by the regulators. The course will focus on understanding the European legal & regulatory environment; the registration procedures that are available, and the structure of the registration dossier. Moreover the course will adopt a practical and interactive approach that will enable you to apply what you have learned to your daily work. Above all, the course will also provides hands on training on approval process in detail.

The course is designed to challenge students to apply what they have learned through the use of interactive exercises, reflection questions, expert live chat and a final assessment at the end of the course.

Course Snapshot

  • Course Code: RYD-115
  • Title of the course: PG Certification in EU Regulatory Affairs (Drugs, Devices and Medical Devices)
  • Nature of the course: Online self paced learning course. Hence, course can be accessed 24×7, across anywhere.
  • Duration of the course: 1 Year
  • Eligibility: Any body who wants to acquire EU drug regulatory affairs competency should attend the course.
  • Course certificate : Certificate will be provided at the end of the successful completion of the course.

Who should attend?

  • Regulatory Affairs professionals who are seeking to improve their skills in the European Drug Regulatory environment.
  • Those moving into regulatory affairs from other areas within a pharmaceutical company (Pharmacists, Clinical Trials, Marketing and others).
  • Anyone wishing to update their knowledge on European regulatory affairs.
  • Regulatory Affairs, Registration and Documentation assistants/officers/managers.
  • Above all, this course is ideal for the business development managers working in pharmaceutical companies, who are handling pharmaceutical business in the European Union.

This European Drug Regulatory Affairs online course utilizes interactive learning tools to guide each participant through to understand the regulatory process of the EU pharmaceutical market. This online certification course will focus on understanding regulatory affairs strategic management skills which is required for effective functioning as regulatory personnel. Indeed, advanced simulation in the course will challenge students to apply what they have learned from the course. In addition, there are advanced learning tools like interactive exercises, reflection questions, and expert live chat which makes the course very interesting.

Key features of the course

  • Orientation to practical understanding in the entire drug regulation, registration procedure of the European Union. Moreover, the course also focuses on Common Technical Documents, guidelines and drug dossier preparations.
  • The course is self paced. Hence, courses can be accessed 24×7, anytime, anywhere across the globe.
  • Moreover, students can download the course material handed out by login to the dashboard. Hence, it helps them to study offline even after completion of the course.
  • Final examination is online. Hence, students can attend the final certification examination at their own convenient date and time.

At Royed Training, we have dedicated International Drug Regulatory Affairs course which covers European Drug Regulatory Affairs course. Executive program in International Drug Regulatory Affairs course covers US, EU, Japan, LATAM, ASEAN, AFRICAN, Middle East / GCC regulation in a single comprehensive course.

Few of the similar courses

European Drug Regulatory Affairs course covers a range of topics related to regulatory affairs in the pharmaceutical and biotechnology industries in Europe. Here are some common areas and subjects that might be included:

Introduction to Regulatory Affairs:

  • Overview of drug development and the role of regulatory affairs.
  • Regulatory agencies and authorities in Europe (e.g., EMA – European Medicines Agency).

European Regulatory Strategic Planning:

  • Developing regulatory strategies for different stages of drug development
  • Regulatory pathways for different types of drugs (e.g., small molecules, biologics, generics, biosimilars).

Submissions Training:

  • Preparing and submitting applications for marketing authorization (MAA) and also variation management.
  • Understanding the Common Technical Document (CTD) format, CMC writing and skill enhancer training on submission management process.

Clinical Development and Trials:

  • Clinical trial regulations in Europe (e.g., GCP – Good Clinical Practice).
  • Investigational Medicinal Product Dossier (IMPD) and Clinical Trial Application (CTA) submissions.

Quality and Manufacturing:

  • GMP (Good Manufacturing Practice) regulations and compliance.
  • Quality control, quality assurance, and quality management systems.

Pharmacovigilance and Post-Marketing Surveillance:

  • Adverse event reporting and pharmacovigilance requirements.
  • Risk management plans and post-marketing studies.

Regulatory Updates and Emerging Trends:

  • Keeping up with changes in European regulatory guidelines and legislation.
  • Exploring emerging trends in regulatory affairs, such as digital health and real-world evidence.

Regulatory Compliance and Inspections:

  • Preparing for regulatory inspections and audits.
  • Ensuring ongoing compliance with regulatory requirements.
Section 1Prime Module - EU Regulatory Filing Strategic Requirements
Lecture 1EU Regulatory System Fundamentals
Lecture 2Introduction to EU Regulation 
Lecture 3Orientation to European Countries and National Regulatory Bodies
Lecture 4EMA and EMA Authorisation Process
Lecture 5EMA and EMA Authorisation Process
Lecture 6Centralised vs DCP vs MRP vs National Procedure - Detailed Strategic Insight
Lecture 7EU MA Application Types and Strategic Planning
Lecture 8EU MA Procedure - Centralised, Decentralised, Mutual Recognition, National Procedure 
Lecture 9EU MA Strategic Planning: Full, Full-mixed, hybrid applications. Generic, Similar biologic application pathway, Well-established use application, Fixed combination application, Informed consent application
Lecture 10Validity of the EU MA  - Renewal steps, Cessation of the marketing authorisation, Significance of "Placed in Union Market", Suspension or withdrawal & EU MA for licensed products
Lecture 11Structured Practical understanding of EU legal bases | Understanding Data Requirements
Lecture 12Practical understanding of EU legal bases for Marketing Authorisation Applications (MAA) | Decision Tree
Lecture 13Centralised Procedure Timetable and Review Logic
Lecture 14DCP / MRP / National Procedure – Practical Workflow Module
Lecture 15EU Procedures Critical Operational Steps - Validation • Clock-Stop • List of Questions • Approval • National Phase
Lecture 16DCP vs MRP Timeline 
Lecture 17EU Adaptive Pathway
Lecture 18European public assessment report (EPAR) - Importance, Component, Management, Updation 
Lecture 19SPOR  - Concept of Master Data Management  
Lecture 20The 'sunset clause' for marketing authorisation of pharmaceuticals
Lecture 21LoQ Response Strategy - EU Regulatory Procedures (CP / DCP / MRP) – Winning the Day 120 / Mid-Cycle Response
Lecture 22Response to list of Questions (LoQ)
Lecture 23Response to list of outstanding issues  (LoOI) - Day 180 / Final Assessment Phase Response
Lecture 24Oral Explanation Training Module - CHMP / CMDh Oral Defence Strategy – From Data to Approval
Lecture 25CHMP - Question Bank  Real-Life Regulatory Questions + Model Answers (CP / DCP / MRP)
Lecture 26Conditional marketing authorisation | Marketing authorisation under exceptional circumstances
Lecture 27Compassionate Use
Lecture 28EU Prime Designation 
Lecture 29MHRA - UK Regulation 
Lecture 30Summary of Product Characteristics 
Lecture 31Drug Registration and Submission Strategic Planning for Russia and EAEU region
Lecture 32Accelerated assessment by EMEA
Lecture 33Certificate of Suitability (CEP) | Significance | Importance | Understanding Regulatory Compliance and Submission Process | Walkthrough
Lecture 34CEP Dossier DMF - Differences
Lecture 35Policy 0070 |  RPDP Submission and Management timeline | Anonymisation Report (AnR) - Significance | AnR in FRDP 
Section 2Clinical Trials Regulation (EU) No 536/2014 – Advanced Training Module
Lecture 36Comprehensive EU Clinical Trial Regulatory Affairs – CTA, CTIS, Strategy & Execution
Lecture 37CTIS Operating Model – Advanced EUClinical Trial Execution Module
Lecture 38CTA Structure: Part I / Part II (EU Clinical Trials Regulation)
Lecture 39Country-wise Part II Requirement Master
Lecture 40CTIS Hands-on Simulation Module Step-by-Step Clinical Trial Submission Exercise (CTR Execution Training)
Lecture 41EU CTR Advanced Module - Substantial Modifications, Safety Reporting, Transition Lessons & End-of-Trial Obligation
Lecture 42IMPD | Significance | Format of IMPD | Differences with CTA, IB, IND
Lecture 43Investigator’s Brochure | Significance | Format of IB | Preparing different sections of IB
Section 3EU Innovation and IP Management
Lecture 44Patent Landscape & Freedom to Operate (FTO) – EU Perspective - Strategic Regulatory + IP Integration Module (Drugs & Biologics)
Lecture 45EU Data Exclusivity, Market Protection & Orphan Exclusivity
Lecture 46Data Exclusivity and Market Protection - Supplementary Patent Protection, Exclusivity, 6/10 Rule, 8+2+1 Formulae
Lecture 47EU Orphan Medicinal Products Regulation
Lecture 48Paediatric use marketing authorisation (PUMA) & Paediatric Investigation Plan (PIP)
Lecture 49EU Supplementary Protection Certificates (SPC) & Paediatric Rewards
Lecture 50Patent vs Regulatory Exclusivity vs Trademark vs Launch Sequencing (EU Perspective)
Lecture 51“No EU-Style Patent Linkage” – What It Really Means (EU vs US)
Lecture 52Key Consideration for Drug Master File Preparation and Submission 
Lecture 53Practical Understanding on Drug Master File Preparation and Submission
Lecture 54Full EU Submission Strategy Planner
Section 4Pharmacovigilance Program
Lecture 55Introduction to Pharmacovigilance |Definition| Importance |Focus Area | Regulatory compliance | PV activities 
Lecture 56Introduction to ADR | Definition | Importance of ADR management | Classification | Prevention of ADR
Lecture 57Terminologies related to ADR 
Lecture 58ADR Reporting System | ADR information loop | ADR reporting system in various countries
Lecture 59DoTS
Lecture 60PSUR
Lecture 61ADR Seriousness Determination 
Lecture 62How regulatory body adopt PV Program in EU?
Lecture 63PSUR
Section 5EU Dossier Preparation | RLD Selection | Stability Requirements
Lecture 64Introduction to Common Technical Document (CTD)
Lecture 65Advance Practical Training on Dossier Preparation focusing on drug registration in export countries 
Lecture 66Chemistry, Manufacturing & Controls 
Lecture 67Modules on Stability Study : Stability Study - Fundamental Understanding | Interchangebility | Reports | API & FPP Stability Study
Lecture 68Review Test on Stability Testing 
Lecture 69Importance of effective dossier management
Lecture 70Importance of effective dossier management
Lecture 71Discussion on 85 common deficiency in CTD submission dossier
Lecture 72Key Consideration for Drug Master File Preparation and Submission 
Lecture 73Practical Understanding on Drug Master File Preparation and Submission
Lecture 74Associated Learning: Site Master File - Detailed Understanding 
Lecture 75DMF Completeness Assessment
Lecture 76Drug Master File - Global Perspective [Across Different Regions]
Lecture 77Data Integrity issues in Pharmaceutical Industry : Detailed Understanding 
Lecture 78RTQs | Response to Queries | How to handle Regulatory Queries  
Lecture 79eCTD Architecture in EU - Electronic Common Technical Document – Structure, Logic, and Execution
Lecture 80EU Module 1 (M1) Specification & Validation Rules – Advanced Regulatory Module
Lecture 81EU Module 1 – Regional Content vs Country-Specific Content
Lecture 82EU eAF, XML Delivery Files, and Submission Gateways
Lecture 83CTD Quality Expectations + Country Comparison in the EU
Lecture 84CTD Module 4 – Nonclinical Package Expectations (EU Perspective)
Lecture 85CTD Module 5 – Clinical Package Expectations (EU Perspective)
Lecture 86How to Identify the Correct EU Reference Product (RLD) - For Generics, Hybrids, and Biosimilars
Lecture 87EU RLD Concept – Foundations | Reference Medicinal Product Strategy for EU Submissions
Lecture 88EU RLD / Reference Medicinal Product Selection - Advanced Case Bank with Detailed Explanation
Lecture 89EU vs US RLD Selection Strategy  | Generics • Hybrids • Biosimilars | Regulatory + Strategic Execution
Lecture 90EU vs US RLD – Master Visual Representation
Lecture 91EU vs US RLD Selection – Step-by-step regulatory thinking model
Lecture 92US & EU Stability Batch Requirement for Multiple Strengths
Section 6Labeling and Artwork Management
Lecture 93CCDS Management 
Lecture 94CCDS Management Tools - Native, AI Plus | Key Functionalities
Lecture 95AI Augmented Labelling Compliance System
Lecture 96Label Drift in CCDS Management | Simulation Case Study | AI Based Workflow in Label Drift detection and management
Lecture 97AI Review of Labels, PI and SMPC with help of the Case Based Simulation | 4 Case Simulations 
Lecture 98CCDS Management Case Study | Pregnancy Warning Upgrade Case Study
Lecture 99CCDS Management Case Study | Dosage Section Conflict | Case Based Analysis
Lecture 100Centralized Artwork Operation | Mechanism | Operation Step Planning 
Lecture 101Case Study on Centralized Artwork Operation  [Recall Management]
Lecture 102Artwork Management Terms | Key Understanding on Terminologies | Usage in Artwork Cases
Lecture 103Source Documents | Artwork Brief
Lecture 104Creating and Reviewing Label Content | Stakeholders of Labelling and Artwork Management | Case Studies 
Lecture 105Change control process for labels | Types of changes | Impact Assessment | Concept of Greyzone Changes
Lecture 106Label Impact Assessment Checklist
Lecture 107Packaging Types & Their Impact on Artwork 
Lecture 108Design tool used in artwork | Esko Platform | Adobe Illustrator | CorelDRAW | File Format | Label Design Workflow and Tool Utilization 
Lecture 109Labelling Management System (LMS) | Understanding of Popular LMS Softwares | Workflow Management | Workflow Automation & Version Tracking | Best Practices
Lecture 110Concept of eLabel (Electronic Labeling) in Pharmaceuticals
Lecture 111Regulatory vs Commercial Perspective of Labelling | Labelling Compliance Function 
Lecture 112Types of Labels 
Lecture 113Artwork & Packaging Lifecycle | Artwork Management Lifecycle Workflow 
Lecture 114Global Artwork Labelling Framework | 5 Case Simulation
Lecture 115Country-Specific Labelling Requirements
Lecture 116Summary of Product Characteristics (SmPC) 
Lecture 117Patient Information Leaflet (PIL)
Lecture 118Summary of Product Characteristics (SmPC) – Review Checklist
Lecture 119Patient Information Leaflet (PIL) – Review Checklist
Lecture 120US Prescribing Information (PI) | Differences with EU SmPC 
Lecture 121US Prescribing Information (PI) - Review Checklist 
Lecture 122Fundamental Understanding on Medication Guide
Lecture 123Regulatory Decision Flow: When Is a Medication Guide Required? - Step Based Decision Making
Lecture 124Medication Guide - Review Checklist | Inspection Checklist 
Lecture 125PI Vs. Medication Guide Comparison 
Lecture 126Patient Information Leaflet (PIL) vs Medication Guide
Lecture 127Label Components | Key considerations for effective designing of label 
Lecture 128Label Review Checklist 
Lecture 129Color Proofing, Dielines & Version Control"
Lecture 130CDR File - Monocarton | Outercarton | Keyline | Design Parameters
Lecture 131Injection Labels - Labels and Cartons
Lecture 132Various Design Component Placement Understanding (Injectables)
Lecture 133Concept of Logo File | Open and Curve File Importance
Lecture 134QC and Proof Reading in Labelling and Artwork
Lecture 135QC and Proofreading Checklist
Lecture 136Template Management and Creative Brief
Lecture 137Pre approval Labelling | ANDA Labelling | ANDA Labelling
Lecture 138Post approval Labelling | PAS | CBE-30 | Annual Reportable Changes
Lecture 139Decision Tree - PAS CBE-0 CBE-30 Annual Reportable Change Determination
Lecture 140Bulk Pack Labelling
Lecture 141Bulk Pack Labelling Checklist 
Lecture 142OTC vs Prescription Labelling | Claim Limitations & Consumer Safety Requirements
Lecture 143OTC vs Prescription (Rx) Label Checklist
Lecture 144OTC Approval Matrix 
Lecture 145OTC Claim Risk Scoring System
Section 7Bioequivalence Study
Lecture 146PKPD in Drug Discovery | PK-PD trial | Understanding PKPD from regulatory perspective in drug approval process
Lecture 147Bioequivalence Study | Study design | Different types of BE Studies
Lecture 148Bioequivalence Study | Study design | Parallel Study | Crossover study design | Other alternative study designs | Blood Sampling Planning  | Analyte | Bioanalytical Methods Validation  | Statistical Model  | Ln Transformation  | Dose normalisation | Confidence interval acceptance criteria
Lecture 149Biopharmaceutical Classification System (BCS) | Types | Biowaivers | BCS tool for drug development and regulatory submission 
Lecture 150Bioequivalence Study - Discussion - Timeline of stability study and bioequivalence study 
Lecture 151Bioequivalence Study - Discussion - Dissolution Testing
Lecture 152Bioequivalence Study - Generic Approval and Additives Labeling Requirements 
Section 8EU Variation Management
Lecture 153EU Variations Legal Framework (Drugs & Biologics) - With Country-Specific Requirements & Operational Differences
Lecture 154Variation Classification | Basis of Classification | US and EU Variation Classification | Other region variation guideline
Lecture 155EU variation -Types, Requirement & Planning - IA, IAIN, IB, II ; US FDA Variation AR, CBE-0, CBE-30, PAS - Strategic Discussion | Similarities & Differentiation
Lecture 156EU Variations Classification – Type IA / IAIN / IB / Type II / Extensions (Line Extensions) - Deep Regulatory Training Module (Execution-Level Understanding)
Lecture 157EU Variation Classification Decision Matrix - Type IA / IAIN / IB / Type II / Extension – Structured Decision Framework
Lecture 158EU Variations: Grouping, Super-Grouping & Worksharing
Lecture 159EU Variations: Centralised vs MRP/DCP vs National – Mechanics & Execution - End-to-End Operational Module
Lecture 160EU Variations – Country-Specific Implementation Issues - Critical Post-Approval Execution Module
Lecture 161EU Variation Impact Dashboard 
Lecture 162Country Wise Variation Tracker (EU focussed)
Lecture 163EU Variation Country Roll out planner
Lecture 164EU Variation Roll Out - Command Center Dashboard 
Lecture 165EU Variations – Invalidation Risks & Day 0 Failures - Critical Regulatory Risk Control Module
Section 9EU Regulation for Medical Device
Lecture 166EU MDR Classification
Lecture 167EU MDD | EU MDR | Articles | Rules | Pages | Annex | Key Changes in EU MDR
Lecture 168EU MDR  | Annexes | Key notes
Lecture 169EU Medical Device Regulation System | MDR | IVDR | UDI | EUDAMED | Requirements for manufacturer | Importer | Distributor | Declaration of Conformity (DoC)
Lecture 170EU MDR Guideline | EU MDR - Annexes 
Lecture 171EU MDR Conformity Assessment procedure | Assessment of various classes and types of the devices | Key points to consider | Conformity assessment master chart 
Lecture 172EU MDR Authorized Representatives | Mandate | Role and Responsibilities 
Section 10Medical Device Labeling Guideline | General Principles | Wherever applicable (specific) Labeling contents 
Lecture 173Medical Device Labeling Guideline | General Principles | Wherever applicable (specific) Labeling contents 
Lecture 174Instruction for Use (IFU) | Design and Development of IFU 
Lecture 175UDI | Different Component | How to design  
Section 11Medical Device Technical File
Lecture 176Medical Device Technical File
Lecture 177Medical Device Dossier Preparation | Section Wise Dossier Preparation | Key Requirements regarding dossier | Points to note regarding each section of the dossier 
Lecture 178Quality Management System (QMS) for medical devices company 
Lecture 179Quality Risk Management | ICH Q9 | ISO 14971 | Principle of Risk Management 
Lecture 180Comparing Medical Device Regulations | 510k Submission | Technical File | Design History File | Design Master File 
Lecture 181Medical Device Essential Principle Checklist | Documentation |  Open file
Lecture 182Implant Card | Regulatory Importance | Content | How to design 
Section 12C-GMP REQUIREMENT FOR MEDICAL DEVICES
Lecture 183c-GMP requirement for medical device
Lecture 184G1 Lecture Premises & Plant Layout Designing
Lecture 185G2 Lecture Sanitation and Hygiene
Lecture 186G3 Lecture Equipment Modules
Lecture 187Production Modules
Lecture 188G5 Lecture Documentation
Lecture 189G6 Lecture Quality Control
Lecture 190Product Complaint
Lecture 191G8 Lecture Storage Module
Lecture 192Product Recall | Product Withdrawal | Handling and Management of Product Recall 
Lecture 193Establishment Inspection Report | 483 Observations | USFDA Warning Letter | Handling of FDA inspection | Closing of Warning Letter 
Lecture 194Documentation | Good Documentation Practices
Lecture 195ISO and ISO Audits
Lecture 196Training on Handling and Management of Data Integrity issues in Pharmaceutical, Biopharmaceutical and Medical Devices Industry
Lecture 197Certification and Legal Requirements for Medical Devices | Conformity Assessment Planning
Section 13CE Marking for medical devices
Lecture 198CE Marking | Introduction | Self Certification | General principles of the CE marking | Manufacturer Responsibilities | Third Party Medical Device Manufacturing & CE Marking | Step By Step CE Marking Process
Lecture 199CE- Self Certification
Lecture 200General principles of the CE marking
Lecture 201Manufacturer Responsibilities
Lecture 202Third Party Medical Device Manufacturing & CE Marking
Lecture 203Classifying Medical Devices Based on the Type of Manufacturing Operation
Lecture 204Few Common Terminologies used in Medical Devices Industry
Lecture 205Step By Step CE Marking Process
Lecture 206Case studies
Section 14TECHNICAL DOSSIER for Medical Device
Lecture 207Introduction to Medical Devices Technical Documentation
Lecture 208Components of technical documentations
Lecture 209Technical Dossier - Information Required
Section 15ISO 13485 Requirements | Audits
Lecture 210ISO 13485:2016 | Audit Format
Lecture 211Review of customer requirements / customer communication
Section 16MDSAP Training
Lecture 212Introduction to MDSAP | Objective | Significance | Role and responsibilities of stakeholders | Key benefits | MDSAP Process structure and Audit Tasks
Lecture 213QMS and MDSAP | Differences and Similarities | MDSAP Vs. ISO 13485 : Key objectives and differences 
Lecture 214MDSAP Stakeholders 
Lecture 215MDSAP Process Structure Audit Task
Lecture 216MDSAP Document Preparation